ClinicalTrials.gg
RecruitingNCT06970509Updated May 14, 2025

Improve the Strategies of Endoscopic and Interventional Treatment of Gastroesophageal Hemorrhage in Portal Hypertension

An observational study in Esophageal Varices and Portal Hypertension, sponsored by Shanghai Zhongshan Hospital. Recruiting at 10 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-14.

Sponsored by Shanghai Zhongshan Hospital · Observational

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,450
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Esophageal and Gastric Varices by Shanghai Zhongshan Hospital — 2 open to participants now, 2 under way, none of them phase 3. Esophageal and Gastric Varices · Shanghai Zhongshan Hospital.

Started
2025
the only one that year
Observational
4 of 13
2 open now
Registered
12th of 13
by date

Among the 13 studies in Esophageal and Gastric Varices by Shanghai Zhongshan Hospital, this one is the only one that started in 2025, is one of 4 observational ones, and was the 12th registered.

Esophageal and Gastric Varices

150 studies on the registry are indexed under Esophageal and Gastric Varices; 39 are open to participants now.

Browse Esophageal and Gastric Varices studies →

Open to participants now

2 of the 13 studies in Esophageal and Gastric Varices by Shanghai Zhongshan Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 20 Esophageal and Gastric Varices studies recruiting now, 13 (65%) set no upper age limit and 1 (5%) stops at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Esophageal and Gastric Varices by Shanghai Zhongshan Hospital, or all of them as a file.
02

Study summary

Endoscopic esophageal variceal ligation combined with gastric variceal embolization using tissue glue is currently the first-choice method for preventing rebleeding in patients with cirrhosis and portal hypertension. However, the rebleeding rate remains relatively high. Factors such as extra-luminal vascular bundles in the esophagus and stomach walls, and portosystemic shunts significantly affect the therapeutic outcomes. Therefore, there is an urgent need to develop an individualized treatment model for esophagogastric varices based on the anatomical and hemodynamic characteristics of the varices, to stratify patient risks and provide tailored treatment options.

Before the treatment of esophagogastric varices, the vascular characteristics of esophagogastric varices are assessed based on imaging data such as portal venous CT and ultrasound, as well as clinical information. Risk factors influencing bleeding from esophagogastric varices are explored, and an endoscopic and interventional variceal stratification and treatment model is constructed to provide patients with personalized options for endoscopic or interventional therapy.

During the treatment of esophagogastric varices, precise endovascular embolization of the source branch vessels of esophagogastric varices is performed based on hemodynamic models. The safety and efficacy of this treatment strategy are verified through randomized controlled clinical trials.

After the treatment of esophagogastric varices, the feasibility of reducing the risk of rebleeding in patients with poor endoscopic outcomes is examined by using drugs that lower portal venous pressure, such as carvedilol or novel oral anticoagulants. Factors influencing recompensation and reversal of portal hypertension are also clarified.

03

Conditions studied

  • Esophageal Varices
  • Portal Hypertension

Keywords

  • Endoscopic Treatment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The data for the training group and internal validation group were derived from patients with portal hypertension and esophagogastric varices who visited Fudan University Zhongshan Hospital from January 1, 2019, to December 31, 2024. The enrolled patients were randomly divided into the training group and internal validation group at a ratio of 3:1.

The external validation group was sourced from patients with portal hypertension and esophagogastric varices who visited participating institutions from January 1, 2019, to December 31, 2024.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Confirmed diagnosis of portal hypertension;
  2. Underwent imaging and endoscopic examination or treatment within one week after admission;
  3. Endoscopy revealed the presence of esophageal and/or gastric varices.

Exclusion criteria

Exclusion Criteria:

  1. CT image slice thickness does not meet the requirements or there are artifacts;
  2. Endoscopy shows no presence of esophageal and/or gastric varices;
  3. Presence of severe life-threatening diseases of the circulatory, hematological, or respiratory systems;
  4. Lack of important historical medical information or other relevant data.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,450 participants (estimated)
Patient registry
No

Groups and cohorts

  • Esophagogastric Variceal Characterization Model for Portal Hypertension Patients

    We have previously preliminarily constructed an automatic segmentation model for intra- and extra-luminal esophageal vessels. This model was validated in the portal venous CT scans of 52 patients with cirrhosis and esophagogastric varices, yielding Dice, Jaccard, 95HD, and ASD scores of 0.903, 0.841, 5.428, and 0.959, respectively, indicating good segmentation performance of the model. To meet the requirements for feature extraction, modeling, and machine learning based on omics characteristics, at least 450 patients are needed. Based on the patient admission situation at our center, we plan to enroll 250 patients in the training set for modeling and 100 patients in the internal validation set, following a 2.5:1 allocation ratio. Other research centers are expected to enroll 100 patients as the external validation group.

  • Endoscopic and Pharmacological Therapy Prognostic Prediction Model

    Taking anticoagulant use as an example, the incidence of portal vein thrombosis (PVT) in patients with portal hypertension is approximately 10-25%. The use of anticoagulant drugs can significantly improve the recanalization of portal vein thrombosis (hazard ratio = 1.3) and improve patient prognosis. With a 1:1 ratio of the two groups, a significance level of 0.05, and a power of 0.9, and following up for 180 days on events such as thrombus recanalization and rupture bleeding of esophageal and gastric varices, the sample size calculation formula for a two-sided test indicates that each group requires 448 cases. Considering a 10% dropout rate, 500 patients will be included in the personalized treatment group for varices and 500 in the traditional treatment group, totaling 1000 patients. Among them, our hospital plans to complete 700 cases, and the multicenter units will complete 300 cases.

06

What researchers measure

Primary outcomes

  1. Gastrointestinal bleeding

    Gastrointestinal bleeding within 1 year

    Time frame: 1 year

Secondary outcomes

  1. Gastrointestinal bleeding

    Gastrointestinal bleeding within 6 months, 3 years, and 5 years

    Time frame: 6 months, 3 years, and 5 years

  2. The occurrence of clinical events

    The occurrence of events such as ascites progression, overt jaundice, changes in portal vein thrombosis, hepatocellular carcinoma, liver transplantation, or survival and death within 6 months, 1 year, 3 years, and 5 years.

    Time frame: 6 months, 1 year, 3 years, and 5 years

07

Study locations

10 of 10 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Dec 2027, 33 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2025
First posted
May 14, 2025
StartActual
Mar 1, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2032
Last update
May 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06970509
Responsible party
Sponsor
First posted
May 14, 2025
Start date
Mar 1, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2032 (estimated)
Last update
May 14, 2025

Study contacts

Yiting Wang, Ph.D.
Contact
wang.yiting@zs-hospital.sh.cn
+86-15221919860
xiaoquan huang, M.D.
Contact
huang.xiaoquan@zs-hospital.sh.cn
+86-18801733835
Shiyao Chen, Ph.D.
principal investigator · Shanghai Zhongshan Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion